Neuphoria Intangible Assets from 2010 to 2026
| NEUP Stock | 4.05 0.02 0.49% |
Intangible Assets | First Reported 2001-06-30 | Previous Quarter 4.8 B | Current Value 4.6 M | Quarterly Volatility 581.5 M |
Check Neuphoria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuphoria Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 15.4 K or Other Operating Expenses of 17.8 M, as well as many indicators such as Price To Sales Ratio of 0.41, Dividend Yield of 0.0 or PTB Ratio of 5.0E-4. Neuphoria financial statements analysis is a perfect complement when working with Neuphoria Therapeutics Valuation or Volatility modules.
Neuphoria | Intangible Assets | Build AI portfolio with Neuphoria Stock |
Evaluating Neuphoria Therapeutics's Intangible Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Neuphoria Therapeutics's fundamental strength.
Latest Neuphoria Therapeutics' Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Neuphoria Therapeutics over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Neuphoria Therapeutics' Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuphoria Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Neuphoria Intangible Assets Regression Statistics
| Arithmetic Mean | 956,014,302 | |
| Geometric Mean | 20,387,495 | |
| Coefficient Of Variation | 221.49 | |
| Mean Deviation | 1,560,475,632 | |
| Median | 9,952,116 | |
| Standard Deviation | 2,117,514,615 | |
| Sample Variance | 4483868.1T | |
| Range | 5.8B | |
| R-Value | 0.66 | |
| Mean Square Error | 2670446.7T | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 278,675,040 | |
| Total Sum of Squares | 71741890.3T |
Neuphoria Intangible Assets History
About Neuphoria Therapeutics Financial Statements
Neuphoria Therapeutics shareholders use historical fundamental indicators, such as Intangible Assets, to determine how well the company is positioned to perform in the future. Although Neuphoria Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Neuphoria Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Neuphoria Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 5.5 B | 5.8 B |
Pair Trading with Neuphoria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neuphoria Stock
Moving against Neuphoria Stock
| 0.84 | VERA | Vera Therapeutics Sell-off Trend | PairCorr |
| 0.72 | EQ | Equillium | PairCorr |
| 0.72 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.65 | DSGN | Design Therapeutics | PairCorr |
| 0.61 | DXB | Dimerix | PairCorr |
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Neuphoria Stock Analysis
When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.